

NOVO NORDISK A S  
Form 6-K  
February 20, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

February 19, 2018

---

**NOVO NORDISK A/S**

(Exact name of Registrant as specified in its charter)

**Novo Allé**

**DK- 2880, Bagsvaerd**

**Denmark**

Edgar Filing: NOVO NORDISK A S - Form 6-K

(Address of principal executive offices)

\_\_\_\_\_

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-\_\_\_\_\_

## Novo Nordisk A/S – Share repurchase programme

**Bagsværd, Denmark, 19 February 2018** – On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 1 February 2018.

Under the programme initiated 5 February 2018, Novo Nordisk will repurchase B shares for an amount up to DKK 2.5 billion in the period from 6 February 2018 to 30 April 2018.

Since the announcement as of 12 February 2018, the following transactions have been made under the programme:

|                                        | <b>Number of<br/>B shares</b> | <b>Average<br/>purchase price</b> | <b>Transaction<br/>value, DKK</b> |
|----------------------------------------|-------------------------------|-----------------------------------|-----------------------------------|
| <b>Accumulated, last announcement</b>  | <b>627,000</b>                |                                   | <b>188,399,577</b>                |
| 12 February 2018                       | 155,000                       | 306.54                            | 47,512,981                        |
| 13 February 2018                       | 150,000                       | 304.69                            | 45,703,149                        |
| 14 February 2018                       | 150,000                       | 302.96                            | 45,444,357                        |
| 15 February 2018                       | 150,000                       | 306.11                            | 45,916,496                        |
| 16 February 2018                       | 150,000                       | 311.92                            | 46,787,811                        |
| <b>Accumulated under the programme</b> | <b>1,382,000</b>              |                                   | <b>419,764,372</b>                |

The details for each transaction made under the share repurchase programme are published on [novonordisk.com](http://novonordisk.com).

Transactions related to Novo Nordisk's incentive programmes have resulted in a net transfer from Novo Nordisk of 16,344 B shares in the period from 12 February 2018 to

16 February 2018. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 64,456,160 B shares of DKK 0.20, corresponding to 2.6% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14 billion during a 12-month period beginning 1 February 2018. As of 16 February 2018, Novo Nordisk has repurchased a total of 4,469,410 B shares equal to a transaction value of DKK 1,373,465,321.

*Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,100 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), Facebook, Twitter, LinkedIn, YouTube*

## **Further information**

### *Media:*

|                      |                 |                                                                |
|----------------------|-----------------|----------------------------------------------------------------|
| Anne Margrethe Hauge | +45 4442 3450   | <a href="mailto:amhg@novonordisk.com">amhg@novonordisk.com</a> |
| Ken Inchausti (US)   | +1 609 786 8316 | <a href="mailto:kiau@novonordisk.com">kiau@novonordisk.com</a> |

### *Investors:*

|                         |                 |                                                                |
|-------------------------|-----------------|----------------------------------------------------------------|
| Peter Hugrefte Ankersen | +45 3075 9085   | <a href="mailto:phak@novonordisk.com">phak@novonordisk.com</a> |
| Hanna Ögren             | +45 3079 8519   | <a href="mailto:haoe@novonordisk.com">haoe@novonordisk.com</a> |
| Anders Mikkelsen        | +45 3079 4461   | <a href="mailto:armk@novonordisk.com">armk@novonordisk.com</a> |
| Christina Kjær          | +45 3079 3009   | <a href="mailto:cnje@novonordisk.com">cnje@novonordisk.com</a> |
| Kasper Veje (US)        | +1 609 235 8567 | <a href="mailto:kpvj@novonordisk.com">kpvj@novonordisk.com</a> |

|                         |               |                                   |                                                              |
|-------------------------|---------------|-----------------------------------|--------------------------------------------------------------|
| <b>Novo Nordisk A/S</b> | Novo Allé     | Telephone:                        | Internet:                                                    |
| Investor Relations      | 2880 Bagsværd | +45 4444 8888                     | <a href="http://www.novonordisk.com">www.novonordisk.com</a> |
|                         | Denmark       |                                   | CVR no:                                                      |
|                         |               |                                   | 24 25 67 90                                                  |
|                         |               | Company announcement No 16 / 2018 |                                                              |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

NOVO NORDISK A/S

Date: February 20, 2018

Lars Fruergaard Jørgensen

Chief Executive Officer